Disease Focus Areas

Although scientific advances have yielded life-saving medical treatments, there are still no cures for—and a lack of basic knowledge about—many debilitating diseases that affect millions worldwide.

SRI's experts in bioscience, imaging technology, and genetic engineering are making significant headway in understanding the environmental and genetic factors contributing to diseases. This knowledge holds the promise of more targeted and effective treatments. SRI researchers devote their efforts to finding cures for some of the world's most serious diseases and conditions, such as:


scientist drawing a chemical structure

SRI is developing a novel point-of-care tool for the early detection of devastating diseases.

bioscience workers in a lab

SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.

twin boys

SRI established the Twin Research Registry as part of its scientific research and efforts to discover more about human behavior. Fraternal and identical twins and multiples of all ages are invited to join the Registry for consideration for research studies.

An SRI vaccine researcher in protective clothing and a mask

To help prepare for next-generation pandemics, SRI is partnering with Stanford University to examine vaccination responses.

cigarette being snapped in half

SRI is analyzing the genetics of smoking and related characteristics, using data from a large-scale National Cancer Institute study on smoking cessation.

gloved hand catching pill capsules coming out of a dispenser

Through a broad range of services for the National Institutes of Health, SRI is accelerating preclinical development of potential therapies for diseases that affect millions of people.

monoclonal antibodies

Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.

scientist working at a computer

SRI has developed a promising new treatment for this cancer of the immune system that affects plasma cells in bone marrow.

hand holding a petri dish of bacterial culture up to the light

Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.

Press Releases

monoclonal antibodies

Sareum announces that SRI's Melissa Works, Ph.D., will present the latest data from the Sareum/SRI collaboration that is developing TYK2 kinase inhibitors as treatments for inflammatory diseases at the Federation of Clinical Immunology Societies (FOCiS) conference.

illustration of the human brain

Researchers have demonstrated that measurements of electrical activity in models of Huntington’s disease could indicate the presence of disease before the onset of major symptoms. Further research on potential biomarkers might one day enable tracking of disease progression.

SRI lab worker

Combining SRI’s expertise in autoimmune and inflammatory diseases with Sareum’s experience in compound design, researchers will advance development of Tyrosine Kinase 2 (TYK2) inhibitors for treatment of autoimmune and inflammatory diseases.

tiger mosquito close-up on human arm

Researchers from SRI International have demonstrated that mosquitoes from Virginia and Georgia can transmit a virus called Chikungunya (CHIKV), which has infected more than 2 million people in Asia, Africa, and parts of Europe since 2005.

Hands holding puzzle pieces

In a step toward understanding possible genetic differences in smoking behaviors, a team of researchers co-led by SRI International has identified a genetic marker associated with smoking quantity in people of African ancestry.

researchers in SRI  lab

SRI International has been awarded a contract worth up to $100.5 million over 10 years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)

DNA gyrase

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time.

Gary Swang, director of SRI International's Center for Health Sciences

Gary E. Swan, Ph.D., director of SRI International's Center for Health Sciences, has been elected by the membership of the Society for Research on Nicotine and Tobacco (SRNT) as its president-elect and will serve as president in 2012.

SRI In the News

SRI International Research: Mosquitoes Common in the U.S. Can Transmit Disease-Causing Virus Endemic to Asia

This article reports that “new research from SRI International finds that mosquitoes commonly found in the United States can be infected with a disease-causing virus from Asia.”

Mosquitoes in the U.S. Can Be Infected with Chikungunya Virus from Asia

This press release reports that new research from SRI International finds that mosquitoes commonly found in the United States can be infected with a disease-causing virus from Asia.

Mosquitoes Appear to be Increasing Health Threat

According to this article, in addition to West Nile Virus mosquitoes can also carry a disease-causing virus from Asia. “In laboratory experiments, researchers at SRI International demonstrated that mosquitoes from Virginia and Georgia can transmit a virus called Chikungunya (CHIKV)..."

Non-profits Partner for Homeland Security

According to the article, SRI International will work to create and commercialize products and to provide training capabilities to allow for easier and more effective communications during emergencies and disasters.

Jon Mirsalis
Fighting the War on Infectious Diseases: An Interview with SRI's Jon Mirsalis

Jon Mirsalis of SRI Biosciences describes how SRI researchers are developing drugs to fight infectious diseases like HIV, malaria, tuberculosis and the flu. Over the years, SRI has helped save thousands of lives by moving drugs from the early discovery stage into human clinical trials.